Technology for Life 1
|
|
- Willis Flynn
- 7 years ago
- Views:
Transcription
1 Technology for Life 1
2 Who we are Global supplier of custom manufactured API s and Intermediates Established in December 10, 1948 Turnover: USD 100M (Oct to Sep. 2016) Number of Workers: 325 2
3 Locations 3
4 Custom Chemical Manufacturing Technology More than 60 different synthesis reactions at commercial scale Strengths: Unnatural Amino Acids Long Chain Peptides Optically Active Compounds 4
5 A look back to the beginning Corporate Entities 1948 founding of Hamari Physicochemical Research Laboratory (closed) 1950 founding of Hamari Chemicals, Ltd., Sakai facility (closed) 1955 founding of Hamari Chemicals, Ltd., Tokyo Office 1961 founding of Hamari Chemicals, Ltd., Takatsuki facility (closed) 1974 founding of Hamari Company Ltd. ( Hamari Health ) 1975 founding of Hamari Chemicals, Ltd., Osaka facility 1980 founding of Yonezawa Hamari Chemicals, Ltd founding of Hamari Chemicals USA Inc founding of Kobe Research Center 2011 founding of Hamari Chemicals USA Inc. San Diego Research Center 2013 founding of Chitose Hamari Chemicals, Ltd. 5
6 A look back to the beginning Historical Active Ingredients 1968 first peptide at commercial scale: L-Glycyl L-Glycine 1984 first US patent: Diltiazem 1985 first US-FDA approved Active Pharmaceutical Ingredient: Ibuprofen 2002 first US-FDA approved New Dietary Ingredient: Zinc Carnosine 2006 first Russia (MHSDRF) approved API: Benfotiamine 2010 first Ukraine (MHU) approved API: Benfotiamine 2012 first India (DCGI) approved API: Benfotiamine 2015 first Australia (TGA) approved API: Zinc Carnosine 6
7 A look back to the beginning Facility Improvements 2008 establishment of high-potency lab and kilo-lab at Osaka facility 2015 establishment of high-potency facility at Chitose facility 2016 recent US-FDA Inspection closure at Yonezawa facility Awards, Certifications and Programs 2013 Kansai Quality Award Winner, Improvement Award 2014 Kansai Quality Award Winner, Award for Excellence 2001 ISO Certification, Yonezawa facility 2011 Kosher Certification 2016 Manufacturing/marketing business license for drugs, Japan Corporate Programs: Corporate Identity (2005); Group QA (2009) ; 5S Housekeeping and Improvement Campaign, Yonezawa facility (1992), Osaka facility (1995), Chitose facility (2014) 7
8 Sales Share by Product Sales volume: 100 million USD Cosmetics & Nutrition Ingredients (9%) Intermediates (13%) Others (7%) Plant Extracts (3%) Active Pharmaceutical Ingredients (68%) 8
9 Sales Share by Region Domestic, Japan (81%) International (19%) Americas (8%) Africa (4%) Russia & Asia (33%) Europe (54%) 9
10 Food Supplement Products Sold in the US Hamari has been supplying food supplement ingredients to the US market for over than 20 years. Chemical Name Zinc Carnosine (L-Carnosine Zinc complex) Benfotiamine (Vitamin B1 derivative) L- Carnosine PepzinGI BenfoPure CarnoLife (β-alanyl-l-histidine) 10
11 Nutraceuticals/Cosmeceuticals OTC Products/Natural Extracts Generic Pharmaceuticals Novel Pharmaceuticals University Technology Licensing Organization Bio-Venture 11
12 Organizational chart of Hamari Group Hamari HQ Yonezawa Hamari Chitose Hamari President Board Members QA Dept. Purchasing Dept. International Dept. Plant Manager Plant Manager Manufacturing Dept. QA Section QC Section Shanghai Office R & D Dept. Group 1 Group 2 Group 3 Group 4 Kobe Lab. Sales &Marketing Dept. Section 1 Section 2 Hamari USA Project Management Office Technology Dept. No.1 Section No. 2 Section No. 3 Section QA Dept. Manufacturing Dept. EHS Office QA Section QC Section Material Management Section Production Management Dept. Manufacturing Dept. Environment Control Dept. QA Dept. QA Section QC Section Engineering & Maintenance Section Packaging & Labeling Section Engineering & Maintenance Section 12
13 Number of Workers Sales R&D QC QA Manuf. Hamari USA (SDRC) Hamari Chemicals Chitose Hamari Yonezawa Hamari
14 Site Function and Business Flow Customer New enquiry! Business Development Hamari USA Hamari Chemicals Hamari Chemicals Chitose Hamari Yonezawa Hamari QC/QA R&D Synthesis & Analysis Hamari USA Hamari Chemicals Yonezawa Hamari Manufacture Hamari Chemicals Chitose Hamari Yonezawa Hamari 14
15 Production Scale <Development Timeline for Pharmaceuticals> Preclinical Clinical Commercial Hamari USA Hamari Chemicals Chitose Hamari Yonezawa Hamari Lab Synthesis (gram to kilo gram scale) Lab, Pilot, Scale up, PQ and PV manufacture (gram to 100kg) Pilot, Scale up, PQ, PV and Commercial manufacture (50 kg to 200 kg) - Synthesis Route Development - Target Compound Synthesis - Synthesis of Samples - (Analysis Development) - Process Optimization - Kilogram Scale Manufacture - GMP Manufacture - Analysis Development and Validation - PQ and PV Manufacture - Drug Master File - Approval Inspection - Commercial Production 15
16 Facilities (1) Osaka Size: 1970 m 2 Waste Water: incineration, public sewage treatment Water: potable, deionized Low Temperature cooling system Total Reactor Capacity: > 21 m 3 Reactors: 50L to 2000L, 17 GL, 10 SUS Low Temp.: -20 C High Temp.: 150 C Autoclaves: 3 reactors at 0.96 MPa (SUS 100L, 500L, Hastelloy 500L) Controlled Areas: 2 lines (200L, 1000L) High potency Lab OEL 4 Lyophilizer 16
17 Facilities (2) Yonezawa Size: 52,806 m 2 Waste Water: incineration, self-process Water: potable, purified, deionized Total Reactor Capacity: >270 m 3 Reactors: 50L to 5000L {72 x GL(148m 3 ); 75 x SUS(123m 3 )} Low Temp.: -90 C High Temp.: 150 C Purification column: 5000L x 2, 2500L x 3, 1200L, 700L x 2, 500L, 250L x 6 Autoclaves: 1 reactor at 0.2 MPa (SUS 1000L); 4 reactors at 0.96 MPa (300L to 2500L); 1 reactor at 6.8 MPa (SUS 500L) Controlled Areas: 4 areas (200L, 800L, 1000L, 2000L, 3000L) Spray Dryer 17
18 Facilities (3) Yonezawa API Plant 18
19 Facilities (4) Chitose Size: 8,000 m 2 Land Size: 56,760 m 2 Water: potable, purified, deionized Acquisition Date: 2013 Total Reactor Capacity: >20 m 3 Reactors: 14 x GL (15 m 3 ); 6 x SUS (4.6 m 3 ) Autoclave: at 6.0 MPa (Hastelloy 300L) Dedicated facility for peptides, high potency facility OEL 4 19
20 Facilities (5) Hamari USA Inc. San Diego Research Center Synthetic Route Scouting Size: 608 m 2 Twelve 8 hoods Two 8 walk-in hoods 5 to 50 L jacketed reactors Parr hydrogenator and autoclave Onsite LC/MS, HPLC and NMR CHIRALPACK 1A, 1B, 1C, 1D and 1E columns Combi-Flash automatic chromatography Custom Peptide Synthesis (LPPS / SPPS / Biotage Microwave Peptide Synthesizer) Access to FTIR, TGA, DSC, XRD 20
21 Audit Experience ( ) from Regulatory Authority 12 from Non-Japanese Clients 9 from Japanese Clients 59 21
22 Clinical Trial Products (IND manufacturing in ) for Non-Japanese Clients 2 for Japanese Clients 19 22
23 DMF s Held by Hamari Quantity Year US DMF , 2009 Europe DMF Korea DMF , 2006, 2008 Japan DMF 27 - Client's DMF 6-23
Brand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationLifeTein in Industrial Production of Therapeutic Peptides. Phil Moore, PhD Director of Business Development LifeTein LLC, NJ, USA
LifeTein in Industrial Production of Therapeutic Peptides Phil Moore, PhD Director of Business Development LifeTein LLC, NJ, USA 1 Outline Market and Technology Trend LifeTein s Technology portfolio LifeTein
More informationNon-GMP and GMP Services From Lab Scale R&D to Bulk API Production
Non-GMP and GMP Services From Lab Scale R&D to Bulk API Production (grams to tons) International and All Encompassing Facilities in Asia, Europe, and North America One Stop Manufacturing from Lab to Commercial
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationDedicated Project Management
Peptides Dedicated Project Management At Lonza, we are committed to our customers success, so it is our mission to help your product reach its full potential. We pride ourselves on delivering high-quality,
More informationHighly Potent APIs The right platform, people and procedures for successful development and manufacturing
Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech
More informationCustom Synthesis. Reliable, Flexible and Competitive THE KEY SOLUTION PROVIDER A FINE CHEMICAL COMPANY. About ISOCHEM
Custom Synthesis Reliable, Flexible and Competitive About ISOCHEM ISOCHEM manufactures products and offers services that meet the most recent and stringent regulatory standards of the Pharmaceutical industry.
More informationEuroPeptides 2014: Workshop Considerations for Peptide Contract Manufacturing: Case Study on Scale-up Considerations
EuroPeptides 2014: Workshop Considerations for Peptide Contract Manufacturing: Case Study on Scale-up Considerations Bruce H Morimoto, PhD Executive Director, Applied Translational Medicine Disclaimer
More informationWelcome to the ChemCon Company Presentation: 6 Steps to Success for our Customers!
Welcome to the ChemCon Company Presentation: 6 Steps to Success for our Customers! The Founder s Vision 1992: Dr. Peter Gockel develops synthesis routes of future Active Pharmaceutical Ingredients at the
More informationHamari Chemicals, Ltd.
amari Chemicals, Ltd. Technology for Life 1 Agenda What amari can offer your company amari s Technology The amari Advantage Core Technology unnatural amino acids and peptides; reduction; chiral technologies;
More informationCUSTOM PEPTIDE SYNTHESIS AT BACHEM
CUSTOM SYNTHESIS CUSTOM PEPTIDE SYNTHESIS AT BACHEM A strong commitment to quality is the basis of our long-standing market leadership We have the capability to synthesize peptides in mg to kg-scale which
More informationXarelto-API Insights. Brochure More information from http://www.researchandmarkets.com/reports/3043740/
Brochure More information from http://www.researchandmarkets.com/reports/3043740/ Xarelto-API Insights Description: Summary The active pharmaceutical ingredients worldwide market is in continuous development
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationCustom Synthesis. Reliable, Flexible and Competitive T H E R I G H T C H E M I S T R Y
Custom Synthesis Reliable, Flexible and Competitive A b o u t I S O C H E M ISOCHEM is a fine chemical company offering custom manufacturing and catalogue products and its primary market is the manufacture
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationGMP and QMS Regulation in Japan
GMP and QMS Regulation in Japan Tomiko Tawaragi Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) August 2 nd, 2014 1 st Brazil-Japan Seminar GMP/QMS GMP : Good Manufacture Practice
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationSpecific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004
Specific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004 Oleg Werbitzky Slide 2 Agenda Market environment Current manufacturing
More information2Technical Support 3Formulation Development 4Proof of Concept 5 GMP Services 6Advanced Drug Delivery 1EUDRAGIT Products Evonik. Power to create.
GMP Services Solutions for Clinical Sample Manufacturing 1 EUDRAGIT Products 2 Technical Support 3 Formulation Development Proof of Concept 4 5 GMP Services 6 Advanced Drug Delivery Evonik. Power to create.
More informationDrug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99
Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99 Printed in the USA. All rights reserved. Copyright 1999 Drug Information Association Inc. THE ACTIVE PHARMACEUTICAL INGREDIENTS STARTING
More informationIron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment,
Brochure More information from http://www.researchandmarkets.com/reports/2980507/ Iron Deficiency Anemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment Description: Iron Deficiency
More informationChina has become the world s factory, second only to the USA in terms of CO 2 emissions among major industrial countries.
PEPTIDES & PROTEINS When it comes to peptide manufacturing, we are all Chinese Jim Hampton, executive vice-president of business development at AmbioPharm, describes sourcing trends for raw materials,
More informationOveractive Bladder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533933/ Overactive Bladder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The Report,
More informationPeptide purification strategies
Särö Conference 2009 Peptide purification strategies Ulf Altenhöner Lonza Exclusive Synthesis R&D Outline Introduction Integrated process development Model-based process development Inspiration Conclusions
More informationInternational GMP Requirements for Quality Control Laboratories and Recomendations for Implementation
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories
More informationChronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
Brochure More information from http://www.researchandmarkets.com/reports/3533727/ Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 Description: SUMMARY The
More informationGUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationCOMPLETE MANUFACTURING FACILITY
COMPLETE MANUFACTURING FACILITY FOR SALE, LEASE OR RENT! Offices, Research & Development, Warehousing and Manufacturing Plant Location: 1901 CLARKWOOD RD CORPUS CHRISTI, TX 78409 (Former Celanese Facility)
More information2010 European Amino Acid Derivatives Product Line Strategy Award
2010 European Amino Acid Derivatives Product Line Strategy Award 2010 Frost & Sullivan 1 We Accelerate Growth Frost & Sullivan s Global Research Platform Frost & Sullivan is entering its 50 th year in
More informationA novel method for the synthesis of peptides
A novel method for the synthesis of peptides in solution DioRaSSP (Diosynth Rapid Solution Synthesis of Peptides) offers substantial benefits for the large-scale synthesis of peptides meeting all the specifications
More informationQuality. Now Certified to ISO 9001:2008
Quality Now Certified to ISO 90012008 Quality Policy It is Peptides International's goal is to achieve complete customer satisfaction by addressing customer needs and delivering what we promise. The company
More information1 The quality management system (QMS) is the corner stone of compliance to GMP. The QMS is made up of several documents, that when followed ensures the GMP compliance of the process, facility and company.
More informationcolorado EXPERTS TAKING CARE
CordenPharma colorado EXPERTS TAKING CARE Our History 1946-1965: Arapahoe Chemicals founded with focus on fine organic chemicals 1965-1994: Acquired by Syntex Corporation with focus on Naprosyn and highly
More informationGuidance for Industry
Guidance for Industry INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationSchweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205. www.schweppesaustralia.com.au
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205 www.schweppesaustralia.com.au Quality Management Systems 1. Quality Management Systems develop, implement, verify
More informationBio-Reagents Gene synthesis Peptide Synthesis Protein Expression Antibody Production. Life Science Products and Services
Bio-Reagents Gene synthesis Peptide Synthesis Protein Expression Antibody Production Life Science Products and Services Since 2002, Biomatik has provided worldwide researchers in life science discovery
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationXarelto-Drug Insights,2014
Brochure More information from http://www.researchandmarkets.com/reports/2977191/ Xarelto-Drug Insights,2014 Description: Xarelto - Drug Insights, 2014 provides Xarelto marketed details and API Manufacturers
More informationDistance Learning in Graduate Courses Applications and Tools in Pharmaceutical Chemistry
ChemEd 201 Distance Learning in Graduate Courses Applications and Tools in Pharmaceutical Chemistry Oliver Grundmann Department of Medicinal Chemistry, College of Pharmacy, University of Florida, U.S.A;
More informationCustomized Nutritional Solutions For Laboratory Animals
A LT R O M I N Customized Nutritional Solutions For Laboratory Animals Dear Sir or Madam, we would like to thank you for a good and successful co-operation in 2008 and furthermore we wish you and your
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationGDUFA (GENERIC DRUG USER FEE ACT): Q&A TELECONFERENCE 26 TH JUNE 2012
The US-FDA pending Generic Drug User Fees Act (GDUFA) is expected to come into force on 1 st October, 2012. A slide set was provided to participants as a comprehensive brief to stimulate questions. Those
More information1) Technical informations. - a) How does it work? - b) Purification - c) Quality Control. 2) Standard synthesis
1) Technical informations - a) How does it work? - b) Purification - c) Quality Control 2) Standard synthesis - a) Standard peptides - b) Modified peptides - c) Shipment and Delivery Time - d) How to order?
More informationPIRAMAL DISCOVERY SOLUTIONS
PIRAMAL DISCOVERY SOLUTIONS Pharma Solutions products and services Delivering Globally Integrated Solutions across the drug lifecycle We are the Contract Development & Manufacturing arm of Piramal Healthcare,
More informationChallenges in Industrial Production of Peptides. Dr. Daniel Bourgin Director of Sales & BD LCM-TIDES, Lonza Ltd. Basel, Switzerland
Challenges in Industrial Production of Peptides Dr. Daniel Bourgin Director of Sales & BD LCM-TIDES, Lonza Ltd. Basel, Switzerland Agenda Market Trend Technology Trend Challenges Lonza s Technology portfolio
More informationGlobal Clinical Supplies Regional Leads EPICS SEPTEMBER 20, 2010
Global Clinical Supplies Regional Leads EPICS SEPTEMBER 20, 2010 Discussion Points Background on the Regional Leads Purpose of the Regional Leads Key Roles & Responsibilities Examples & Case Studies Global
More informationReagents, Tools, and Services for Pharma Manufacturing. GMP Grade Advanced Intermediates, and Customized Solutions
Reagents, Tools, and ervices for Pharma Manufacturing MP rade Advanced Intermediates, and Customized olutions ur Expertise, Your uccess Roche Custom Biotech offers a growing portfolio of generic and customized
More informationDISCUSSION SUMMARY. Q3 & 9M FY16 Results Highlights. Consolidated Financials. About Us. Business Strategy & Outlook
DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q3 & 9M FY16 RESULTS UPDATE FEBRUARY 2016 DISCUSSION SUMMARY Q3 & 9M FY16 Results Highlights Consolidated Financials About Us Business Strategy & Outlook 2 SAFE
More informationGuidance for Industry
Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for Synthetic Peptide Substances Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
More informationPharmaceutical Quality Systems: US Perspective
Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical
More informationSupply Chain Challenges and Risk Management
Supply Chain Challenges and Risk Management Presented by Steve Williams Director SeerPharma P/L 21 st April 2009 PDA April 09 SW 1 Supply Chain - Some Useful Guidance cgmp Annex 8 cgmp Chapter 7 ICH Q7
More informationContaminated Products Insurance Application Form
Contaminated Products Insurance Application Form APPLICANT S INFORMATION Name of Applicant Mailing address Contact Person Name: Email and Phone number: Website address Years in operation Business Description:
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
More informationRecent Updates on European Requirements and what QPs are expected to do
Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status
More informationGRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors
GRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors This course is a distance-learning program that will culminate in a Graduate
More informationGuidance on Qualification of existing facilities, systems, equipment and utilities
QUALIFICATION_EXISTING_EQUIPMENT_FINAL page 1 / 16 1. Acknowledgement...3 2. Introduction...3 3. Scope...4 4. Regulatory requirements...4 5. Guidance...4 5.1 Risk Assessment... 4 5.2 Procedure... 7 5.3
More informationOptimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy
Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting
More informationGMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
More informationProviding Trusted and Innovative Solutions t o the Life Science Communities
Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development
More informationHow To Make A Drug From A Peptide
MODERN PERSPECTIVES ON PEPTIDE SYNTHESIS INTRODUCTION WHITEPAPER www.almacgroup.com The complexity of synthetic peptide products, whether as reagents used in research or as therapeutic APIs, is increasing.
More informationSosei acquires Jitsubo, a leading Japanese peptide technology company
Sosei acquires Jitsubo, a leading Japanese peptide technology company Tokyo, Japan 11 December 2014: Sosei Group Corporation ( The Group ; TSE Mothers Index: 4565) is pleased to announce that at the meeting
More informationStart-up to International Business
Start-up to International Business POSAT Seminar 18-19 May 2015 www.almacgroup.com 2 Outline The story. Company background Dealing with growth The importance of strategy The message. How companies face
More informationHow companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
More information2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
More informationNatural Health Products Directorate - Direction des produits de santé naturels
Site Licensing & Good Manufacturing Practices Requirements for Natural Health Products in Canada Canadian Association of Professional Regulatory Affairs Annual Education Day - June 5, 2012 Raymond W. Tsang,
More informationUSP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants
USP Pharmaceutical Ingredient Supplier Qualification Program Manual for Participants UNITED STATES PHARMACOPEIA Drug Substance Supplier Qualification Program ICE This manual provides information to drug
More informationGreen Product Management
Green Product Management Wistron is not only a professional product design, manufacturing and aftersales service company, but also a provider of technical services. Equally our product development system
More informationMicrobiology and Auditing. Don Singer
Microbiology and Auditing Don Singer ASQ Northeast Pharmaceutical GMP/Quality Conference 2011 Through the eyes of a Microbiologist Microbiology Audit = Inspection / Investigation Systematic Auditing Planning
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationGood Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing
Good Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing Katherine L. Ulman and Dr. Patricia Rafidison Dow Corning Healthcare About the Authors
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationEngineering Nanomedical Systems
BME 695 November 8, 2011 Engineering Nanomedical Systems Lecture 15 GMP and issues of quality control manufacture of nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor
More informationOptimize Your Process Operations by Improving Process Monitoring
Integral Process Ana Optimize Your Process Operations by Improving Process Monitoring All industrial processes have a common need reliable, accurate, and timely methods for analyzing process chemistry.
More informationAuditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
More informationClinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.
Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma
More informationexperiment5 Understanding and applying the concept of limiting reagents. Learning how to perform a vacuum filtration.
81 experiment5 LECTURE AND LAB SKILLS EMPHASIZED Synthesizing an organic substance. Understanding and applying the concept of limiting reagents. Determining percent yield. Learning how to perform a vacuum
More informationMeriCal Quality Profile
January 5, 2015 Dear Valued Customer, Since the implementation of new federal regulations, MeriCal Inc. has received a large volume of questionnaires and surveys regarding our services and procedures.
More informationExperimental procedures. Solid phase peptide synthesis (SPPS)
Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is The Royal Society of Chemistry 214 Experimental procedures Solid phase peptide synthesis (SPPS) Solid phase
More informationPlanning Engineering Projects management of Pharmaceutical Plants
Planning Engineering Projects management of Pharmaceutical Plants Contrà S. ANNA 1/5 35012 CAMPOSAMPIERO (PD) www.tsaonline.it tel. 0039-0495792435 fax 0039-0499306065 Chemical and Pharmaceutical Engineering
More informationFOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005)
FOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005) Dr.R.MANAVALAN, M.Pharm., Ph.D. Professor and Research Director, Department of Pharmaceutics,
More informationThe Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
More informationFOOD QUALITY AND ANALYTICAL CONTROL. Prof.ssa Patrizia Pinelli Dott. Leonardo Borsacchi
FOOD QUALITY AND ANALYTICAL CONTROL Prof.ssa Patrizia Pinelli Dott. Leonardo Borsacchi Monday Tuesday Wednesday Thursday Friday Saturday 8:00 9:00 10:00 11:00 12:00 (6/011 D6) 13:00 (6/011 D6) 14:00 (6/011
More informationCelCulture. CelCulture CO2 Incubator Model CCL-170_-_. CO2 Incubator with Integrated Cooling System Solution for Highly Specialized Applications
1 CO2 Incubator Model CCL-170_-_ CO2 Incubator with Integrated Cooling System Solution for Highly Specialized Applications Welcome to Esco Esco s Vision is to provide enabling technologies for scientific
More informationPharmaceutical Laboratory. Company acquisition
Pharmaceutical Laboratory Company acquisition Former Bristol-Myers Squibb site Dry production site 13,000 m². of premises on a site of 12.6 hectares 35 qualified people Company looking for a buyer 1 External
More informationOutsourcing Laboratory Practices
Outsourcing Laboratory Practices V.K. Bafna Managing Director TCR Engineering Services www.tcreng.com The World is Flat Outsourcing to India Beyond Information Technology Clinical Trials Medical Transcription
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationJohnson Controls Sustainability Supplier Rating Supplier info
Supplier info *First name *Last name *Company *Vendor ID *My company supplies the following Johnson Controls division(s): {Choose all that apply} ( ) Automotive Experience ( ) Building Efficiency ( ) Power
More informationDrug Regulations in India Dr. Surinder Singh Drugs Controller General (India) Meeting With Ambassadors / High Commissioners of African Countries 24
Drug Regulations in India Dr. Surinder Singh Drugs Controller General (India) Meeting With Ambassadors / High Commissioners of African Countries 24 th April 2009, New Delhi Flow of presentation About Indian
More informationCEM, First in Microwave Peptide Synthesis
CEM, First in Microwave Peptide Synthesis In 2002, a CEM biochemist named Jonathan Collins presented his concept of a microwave-assisted peptide synthesis system to several colleagues. Collins concept
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationDepartment of Food Science Food Processing FSE98(10-99)
Department of Food Science Food Processing FSE98(10-99) Choosing and Using a Copacker John E. Rushing, Ph.D. What is a copacker? Copackers manufacture and package foods for other companies to sell. These
More information